Behavioral Medicine and Addictions Research, Butler Hospital, Providence, RI, USA.
Department of Health Law, Policy & Management, Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA.
AIDS Behav. 2021 Apr;25(4):1013-1025. doi: 10.1007/s10461-020-03062-2. Epub 2020 Oct 12.
Alcohol use contributes to the progression of liver disease in HIV-HCV co-infected persons, but alcohol interventions have never addressed low levels of alcohol use in this population. We enrolled 110 persons consuming at least 4 alcoholic drinks weekly in a clinical trial comparing two active 18-month long interventions, delivered every 3 months by phone, brief advice about drinking versus a motivational intervention. Final assessment was at 24 months. MI had larger reductions in alcohol use days than the BA arm at all follow-up assessments. The treatment by time effect was not significant for days of drinking (p = 0.470), mean drinks per day (p = 0.155), or for the continuous FIB-4 index (p = 0.175). Drinking declined in both conditions from baseline, but given the small sample, we do not have sufficient data to make any conclusion that one treatment is superior to the other.Trial Registry Trial registered at clinicaltrials.gov; Clinical Trial NCT02316184.
酒精的摄入会导致 HIV-HCV 合并感染患者的肝病恶化,但在该人群中,酒精干预措施从未针对低水平饮酒问题进行干预。我们招募了 110 名每周至少饮用 4 份含酒精饮料的患者,他们参加了一项临床试验,比较两种为期 18 个月的主动干预措施,每 3 个月通过电话进行一次,即对饮酒的简短建议与动机干预。最终评估在 24 个月进行。在所有随访评估中,与 BA 组相比,MI 组的饮酒天数减少幅度更大。治疗时间效应在饮酒天数(p=0.470)、平均每日饮酒量(p=0.155)或连续 FIB-4 指数(p=0.175)方面均无统计学意义。两种情况下的饮酒量均从基线开始下降,但鉴于样本量较小,我们没有足够的数据来得出任何一种治疗方法优于另一种的结论。试验注册临床试验在美国临床试验数据库注册;临床试验 NCT02316184。